Address: Unit 7 – RB Building, 557 Harrow Road, Kensal Green, London W104RH,United Kingdom
Tel: 0800 9179548
Web: http://www.hra-pharma.com/
HRA Pharma is an emerging pharma company that engineers drugs, devices and services in reproductive health and endocrinology and makes them available worldwide. By targeting niche market segments and designing custom-made solutions, the company’s objective is to fill therapeutic gaps.
HRA Pharma wants its customers and partners to enjoy working with them; to expect and receive a ‘Boutique’, experience – dealing with approachable and professional people in an emerging and independent organisation, where they feel that the interaction is personal and tailored to their needs. A refreshing experience where they find the honest and personal style very engaging, and appreciate the developing socially conscious side of HRA’s business.
Women’s health:
– Norlevo
– ellaOne
– Cicatridine
– GiMyso
– Mona Lisa
Endocrine Diseases
– Lysodren
– Lysosafe
Inês Correia, general manager of the Iberia affiliate of HRA Pharma, a fast-growing consumer healthcare company and leader in women’s health, discusses her transition to the company and challenges in…
Erin Gainer, the CEO of HRA Pharma, reveals how the company has significantly grown its business in the fields of women’s health and endocrinology over the past decade to become…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
The Window Conference Center is hosting at least six pharmaceutical events within a month, and has a broad prior history of orchestrating such occasions. How important is the pharmaceutical industry…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
You joined Apodi in 2008, after a hiatus from the industry following the sale of your previous company, In2Focus, in 2007. What has been the most challenging aspect of your…
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
See our Cookie Privacy Policy Here
